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Abstract 
Background: The incidence and prevalence of cardiovascular disease (CVD) increases with 
age. Some evidence suggests that mental stress may increase plasma homocysteine (Hcy), an 
amino acid relating to CVD. However, none of these studies assessed age effects on Hcy 
stress reactivity, nor did they control for age. The objective of this study was a) to investigate 
whether Hcy reactivity to psychosocial stress differs between younger and middle-aged to 
older men and b) to study whether psychosocial stress induces Hcy increases independent of 
age. 
Methods: 28 younger (20-30 yrs) and 22 middle-aged to older (47-65 yrs) apparently healthy 
men underwent an acute standardized psychosocial stress task combining public speaking and 
mental arithmetic in front of an audience. Blood samples for Hcy measurements were 
obtained immediately before and after, as well as 10 and 20 minutes after stress. Moreover, 
salivary cortisol was repeatedly measured to test the effectiveness of the stress task in 
triggering a neuroendocrine stress response.  
Results: Hcy reactivity to stress differed between age groups (F(1.4, 60.7) = 5.41, p =.014). 
While the older group displayed an increase in the Hcy response to stress (F(2.5, 39.8) = 3.86, 
p =.022), Hcy levels in the younger group did not change (p=.27). Psychosocial stress per se 
did not change Hcy levels independent of age (p=.53). 
Conclusions: Our findings suggest that psychosocial stress does not evoke an Hcy response 
per se, but only in interaction with age pointing to a mechanism by which mental stress may 
increase CVD risk in older individuals. 
Key words: homocysteine, age, stress reactivity, acute mental stress, TSST, cardiovascular 
disease risk 
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Introduction  
The incidence and prevalence of atherosclerotic and thrombotic cardiovascular disease 
(CVD) increases progressively with age (Herrera et al., 2010). To explain the higher 
atherothrombotic risk and ultimately cardiovascular mortality with increasing age, several 
studies have attempted to elucidate changes in atherogenic and thrombogenic factors during 
aging (Weinsaft and Edelberg, 2001; Torregrossa et al., 2011).  
Homocysteine (Hcy) has been firmly established as an independent predictor of 
atherosclerotic and thrombotic cardiovascular disease (CVD) (McCully, 1996; Wald et al., 
2002). Moreover, plasma Hcy tends to rise in healthy persons parallel with age (Ellinson et 
al., 2004). Hcy is a sulfur-containing amino acid derived from the dietary amino acid 
methionine (Castro et al., 2006). Hcy plasma levels are regulated by a complex metabolic 
pathway involving genetics, nutrition, and renal function (Refsum et al., 1998; Castro et al., 
2006). Notably, the age-related increase in Hcy levels may result from suboptimal intake or 
absorption of vitamin B6, B12, and folate acting as key cofactors for Hcy metabolism, and 
decreased renal clearance of Hcy (Selhub et al., 1993; Castro et al., 2006). The mechanisms 
by which elevated Hcy levels relate to CVD are not fully understood. However, compelling 
evidence from experimental models indicates that Hcy is responsible for arterial changes and 
vascular damage by impairing bioavailability of nitric oxide and antioxidant defense, 
enhancing lipid peroxidation (Papatheodorou and Weiss, 2007), causing protein modification 
(Jakubowski, 2001, 2004), and thrombosis (Undas et al., 2006; Jakubowski et al., 2008), or 
activating inflammation (Jakubowski, 2005; Bogdanski et al., 2008). Notably, abundant 
epidemiological and experimental evidence suggests a potential causal role of mild to 
moderate hyperhomocysteinemia in the pathogenesis of CVD (McCully, 1996; Wang et al., 
2007; Dragani et al., 2012). However, recent intervention trials have raised suspicion about 
this notion as treatment of mild hyperhomocysteinemia with B vitamins resulted in lower Hcy 
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levels without subsequent reduction of CVD incidence (Clarke et al., 2010). Interestingly, the 
vitamin B induced Hcy reduction was associated with reduction of stroke risk (Saposnik et al., 
2009). In addition, some Mendelian randomization studies found an increased CVD risk in 
subjects with lifelong mildly to moderately elevated plasma Hcy due to polymorphisms in 
Hcy-metabolizing enzymes (Wald et al., 2002; Casas et al., 2005; Cronin et al., 2005), 
whereas others did not detect an association (Clarke et al., 2012). Notably, intervention trials 
as well as Mendelian randomization studies have several limitations (for review see 
(Smulders and Blom, 2011)) and results need to be interpreted with care.  
In addition to age, Hcy, and their interaction, mental stress is a further factor that has 
been associated with CVD risk. Accumulating evidence indicates a strong impact of mental 
stress on the pathogenesis of atherosclerotic and thrombotic CVD (Brotman et al., 2007). It 
has been suggested that repeated episodes of acute or chronic stress may initiate or promote 
the atherosclerotic process via effects on Hcy (Black and Garbutt, 2002). Indeed, a study 
assessing basal Hcy levels in non-smoking war veterans with and without Post Traumatic 
Stress Disorder (PTSD) found highest Hcy levels in war veterans with PTSD (Jendricko et al., 
2009). As PTSD is likely to add to chronic stress load, the study’s findings point to a potential 
association between stress and higher Hcy plasma levels. In terms of acute stress reactivity, 
studies in rodents show increases in plasma Hcy immediately after restrained stress (de 
Oliveira et al., 2004; de Souza et al., 2006). However, human studies investigating Hcy 
reactivity to acute stress are rare and results are contradictory. While two studies reported 
increases in plasma Hcy levels in response to acute mental stress in middle-aged to older 
women (Stoney, 1999) and in young men (Sawai et al., 2008), another study including pre- 
und postmenopausal women found no Hcy stress reactivity (Farag et al., 2003). Moreover, 
none of these studies assessed age effects on Hcy stress reactivity, nor did they control for 
age. To date, it has not yet been investigated whether a potential Hcy change following acute 
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mental stress might be age-dependent, which could shed light onto the complex mechanisms 
in the interface between age, Hcy, stress reactivity, and their interactions.  
Therefore, we aimed to elucidate whether a potential Hcy stress reactivity differs 
between younger and middle-aged to older men. We hypothesized that older men show higher 
Hcy responsiveness to acute stress than younger men. Moreover, we investigated whether 
Hcy levels do change following mental stress independent of age.  
 
Methods 
Participants  
This study is part of a larger project assessing psychobiological stress reactivity in 
healthy men (Wirtz et al., 2008). The Ethics Committee of the State of Zurich, Switzerland, 
formally approved the research protocol. For the purpose of this part of the study we 
intentionally selected from an existing study sample of N = 63 apparently healthy men aged 
between 20 to 65 yrs a group of younger men without age-related CVD risk (age range 20-30 
yrs) and a group of middle-aged to older men with age-related CVD risk (age range 45-65 
yrs) for analysis of Hcy levels from frozen plasma samples. Notably, the threshold of 45 yrs 
of age for increased age-related CVD risk was based on previous literature (Roger et al., 
2011). Applying these age criteria for group inclusion the final sample of this study comprised 
28 subjects aged 20 to 30 yrs (“younger men”) and 22 subjects aged from 47 to 65 yrs (“older 
men”) rendering a total sample size of N=50. All subjects provided written informed consent.   
The study was conducted between April 2004 and August 2005. In the main study, we 
intentionally recruited nonsmoking men aged between 20 and 65 years who were in good 
physical and mental health as confirmed by a telephone interview using an extensive health 
questionnaire. Specific exclusion criteria were obtained from the subjects’ self-report and 
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included clinical psychosomatic and psychiatric diseases, regular strenuous exercise, alcohol 
and illicit drug abuse, any heart disease, varicosis or thrombotic diseases, elevated blood 
sugar and diabetes, elevated cholesterol, liver, and renal diseases, chronic obstructive 
pulmonary diseases, allergies and atopic diathesis, rheumatic diseases, and current infectious 
diseases. In addition, participants were included only if they reported taking no prescribed 
and/or over-the-counter medication, either regularly or occasionally. In case of inconclusive 
personal or medication history, the subjects’ primary care physician was contacted for 
verification.  
 
Study design 
Subjects were tested between 1400h and 1600h. The night before the test, they 
abstained from physical exercise, alcohol, and caffeinated beverages. To inflict acute 
psychosocial stress, we applied the standard protocol of the widely used Trier Social Stress 
Test (TSST) combining a five minute preparation phase followed by a five minute mock job 
interview, and a five minute mental arithmetic task in front of a panel of one man and one 
woman (Kirschbaum et al., 1993). The TSST has been shown to reliably induce profound 
endocrine and cardiovascular responses (Kirschbaum et al., 1993; Dickerson and Kemeny, 
2004). After test completion, subjects remained seated in a quiet room for 60 minutes.  
Blood samples for assessment of Hcy were taken immediately before (baseline) and 
after, as well as 10, and 20 minutes after completion of the TSST. For vitamin B12, folate, 
and creatinine, another blood sample was taken at baseline. For determination of salivary free 
cortisol levels, samples of saliva were collected immediately before (baseline) and after, as 
well as, 10, 20, 30, 45, and 60 minutes after TSST completion. BP was measured immediately 
before and 30 minutes after stress by sphygmomanometry (Omron 773, Omron Healthcare 
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Europe B.V. Hoofddorp, Netherlands) and mean arterial pressure (MAP) was calculated by 
the formula (2/3×mean diastolic BP)+(1/3 mean systolic BP). 
 
Biochemical analyses 
For analyses of Hcy, vitamin B12, folate, and creatinine, venous blood was drawn 
through an indwelling forearm catheter into EDTA-coated monovettes (Sarstedt, Numbrecht, 
Germany), and immediately centrifuged for 10 minutes at 2000 x g and 4°C. Obtained plasma 
was stored at -80°C until analysis.  
Hcy was determined by fully automated particle-enhanced immunonephelometry with 
a BN II System (Siemens Healthcare Diagnostics, Eschborn, Germany) by enzymatic 
conversion to S-adenosyl-homocysteinee (SAH). Inter- and intra-variance was 5.6% and 
3.4%, respectively.  
Plasma concentrations of vitamin B12 and folate were measured by means of a 
competitive chemiluminescent immunoassay with an Access™ Immunoassay System 
(Beckman Coulter, Krefeld, Germany) according to the manufacturer’s instructions. Inter- and 
intra-variance of the vitamin B12 assay was 4.2% and 3.8%, respectively. Inter- and intra-
variance of the folate assay was 3.6% and 3.1%, respectively. 
Plasma creatinine was determined on the Dimension VistaTM clinical chemistry 
system (Siemens Healthcare Diagnostics) with a commercially available assay based on a 
modification of the Jaffé method according to the manufacturer´s instructions. Inter- and 
intra-variance was 2.5% and 1.2%, respectively.  
For cortisol, saliva samples were collected in Salivettes (Sarstedt, Sevelen, 
Switzerland) and stored at -20°C until analysis. Centrifugation of thawed saliva samples was 
at 3000 x g, yielding low-viscosity saliva. Free cortisol concentrations were determined using 
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a commercial chemiluminescence immunoassay (LIA) with high sensitivity of 0.16 ng/ml 
(IBL Hamburg, Germany). Inter- and intra-variance was < 11.5% and 7.7%, respectively.  
 
Statistical analyses 
Data were analyzed using SPSS Inc. version 17.0 for Windows (Chicago, IL, USA) 
and presented as mean ± SEM. All tests were two-tailed with the significance level set at p ≤ 
.05. G*Power 3.1 analysis revealed that the optimal total sample size to predict group 
differences in Hcy stress reactivity was N = 46 for detecting a small effect size of f = 0.10 in 
repeated measurement analysis of variance (ANOVA; with Hcy as repeated factor with four 
measurements that intercorrelate >.90) with a power of .95. Prior to statistical analyses, data 
were tested for normal distribution and homogeneity of variance using Kolmogorov-Smirnov 
and Levene’s tests. Skewed Hcy values were logarithmically transformed to approach normal 
distribution. 
Differences between the characteristics of the two subject groups were calculated 
using univariate analysis of variance (ANOVA; Table 1).  
To test whether the stressor evoked a significant neuroendocrine stress response, we 
calculated repeated measures ANOVA with group (younger vs. older men) as the independent 
variable and the eight time points in which cortisol was measured as repeated dependent 
variable.  
In order to investigate age effects on Hcy stress reactivity, we calculated repeated 
measures ANCOVA with group (younger vs. older men) as independent variable and the four 
Hcy measurements as repeated dependent variable. Post-hoc testing of significant Hcy effects 
comprised separate recalculations of repeated ANCOVAs for each group. 
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To test for overall Hcy stress reactivity independent of group i.e. age, we further 
performed repeated measures ANCOVA with both groups combined to one single group as 
independent variable and the four Hcy measurements as repeated dependent variable, while 
controlling for age as covariate. Because of known associations with age (Roberts and 
Williamson, 2002; Higashi et al., 2012), we controlled in all ANCOVAs of Hcy data for 
possible confounding effects of the CVD risk factors body mass index (BMI) and MAP by 
including these variables as covariates. In light of previously reported associations between 
vitamin B12, folate, and creatinine (Hcy confounders) with plasma Hcy levels at rest (Refsum 
et al., 1998; Castro et al., 2006), we additionally controlled for Hcy confounders in Hcy 
analyses. Moreover, in complementary analyses testing for group differences in Hcy stress 
reactivity we additionally accounted for baseline differences in Hcy levels by subtracting 
baseline Hcy levels from all Hcy measurements and repeated the respective ANCOVA 
analysis. 
Effect size parameters (f) were calculated from partial η2-values and are reported 
where appropriate (effect size conventions: f: .10 = small, .25 = medium, .40 = large). 
 
Results  
Subject’s characteristics  
Table 1 provides the characteristics of subjects in the younger and older age group. 
BMI, MAP and plasma levels of Hcy at rest were higher in older as compared to younger 
subjects. In addition, the older group had lower baseline levels of salivary cortisol (p = .041). 
There were no group differences in plasma levels of vitamin B12, folate and creatinine. 
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Validation check of the stress protocol  
ANOVA for repeated measurements revealed significant salivary cortisol increases in 
response to stress across both age groups (main effect of stress in the total group: F(2.7/125.9) 
= 29.39, p = <.001, η2 = .39; main effect of stress in the younger group: F(2.6/67.7) = 11.73, p 
< .001, η2 = .31; main effect of stress in the older group: F(1.6/32.3) = 26.90, p < .001, η2 = 
.57)) (Fig. 1). Stress reactivity differed significantly between groups (interaction group-by-
stress: F(2.7/125.9) = 4.51, p = .006, η2 = .09) with higher stress reactivity in the older group.  
Please insert figure 1 around here.  
 
Homocysteine stress reactivity  
Repeated measures ANCOVA revealed that Hcy reactivity to stress differed between 
age groups (interaction age-by-stress: F(1.3, 60.3) = 3.89, p =.042, η2 = .08, f = 0.29). This 
effect became even stronger when controlling for the full set of confounders (interaction age-
by-stress: F(1.4, 60.7) = 5.41, p =.014, η2 = .11, f = 0.35) (Fig. 2). With exception of BMI (p = 
.038), none of the confounders significantly related to Hcy stress reactivity (p’s>.16). 
Additional adjustment of repeated Hcy measures to Hcy baseline levels in complementary 
analyses did not change results (interaction age-by-stress: p = .014). To address the direction 
of the observed group difference we calculated post hoc tests. We found that independent of 
confounders, the older group displayed an increase in Hcy levels in response to stress (main 
effect stress: F(2.5, 39.8) = 3.86, p =.022, η2 = .19, f  = 0.48), while Hcy levels in the younger 
group did not significantly change (main effect stress: F(1.3, 29.3) = 1.31, p =.27, η2 = .06). 
As depicted in Fig. 2 in the older group Hcy plasma levels where highest immediately after 
stress and approached baseline levels during the recovery period. 
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Notably, overall (i.e. in the combined total group), psychosocial stress did not 
significantly change Hcy levels independent of age, BMI, and MAP (p=.32) even when 
additionally controlling for Hcy confounders (p=.53).  
Please insert figure 2 around here.  
 
Discussion 
To our knowledge, this is the first study to investigate whether Hcy responsiveness to 
acute stress differs between older and younger men. We intentionally selected from an 
existing sample of apparently healthy men aged between 20 to 65 yrs a group of younger men 
without age-related CVD risk (age range 20-30) and a group of middle-aged to older men 
with age-related CVD risk (age range 47-65 yrs)(Roger et al., 2011). We found an increase in 
plasma Hcy immediately after stress in the older group, but none in the younger group. In 
other words, while the older group showed Hcy stress reactivity, Hcy levels in the younger 
group did not significantly change. Associations were of medium to large effect size and 
independent of CVD risk factors, Hcy confounders, and Hcy baseline levels. Furthermore, we 
found that stress per se did not change Hcy levels independent of age (or age group). Notably, 
our psychosocial stress protocol induced significant increases in free salivary cortisol in both 
age groups demonstrating the effectiveness of our stress protocol in triggering a 
neuroendocrine stress response. While the cortisol stress response was elevated in the older 
group corroborating previous findings (Kudielka et al., 2004), controlling for total cortisol 
secretion (by calculating the area under the curve (Pruessner et al., 2003)) did not 
significantly relate to Hcy stress reactivity (p’s > .60) nor did it change any of the reported 
results on Hcy stress reactivity (data not shown).  
What are the potential implications of these findings und how do they relate to the 
literature? Our data suggest that psychosocial stress does not evoke a Hcy response per se, but 
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only in interaction with age. Numerous case-control and prospective studies have shown that 
mildly to moderately elevated plasma Hcy levels are positively associated with 
atherothrombotic vascular disease in the coronary (Lee et al., 2003), cerebral (Perry et al., 
1995; Eikelboom et al., 2000), and peripheral arteries (Graham et al., 1997; Humphrey et al., 
2008). A previous meta-analysis of prospective studies found that 25% (or, typically, 3 
μmol/L) lower plasma Hcy is associated with an 11% lower risk of coronary heart disease and 
a 19% lower risk of stroke (2002). In our dataset, mean Hcy increase in response to stress in 
the older group was 2 μmol/L, with a highest observed absolute increase of 4.8 μmol/L. Given 
these increase levels, the findings of our study possibly point to a mechanism by which 
mental stress increases CVD risk in older individuals. However, it has not yet been 
investigated whether short-term Hcy increases as observed in our study relate to CVD and 
CVD risk. Moreover, despite in the older group increased Hcy levels in response to stress 
approached baseline levels in the course of the recovery period, it might be speculated that 
stress-induced transient elevations in Hcy levels may accumulate in the long term and 
contribute to higher basal plasma Hcy levels in older individuals. However, further studies are 
needed to determine whether in older persons increased Hcy levels following stress might 
contribute to elevated basal plasma Hcy levels.  
The hitherto published studies on Hcy stress reactivity are controversial, as a Hcy 
increase in response to stress could not always be detected. Our study provides first 
indications that aging affects the Hcy response to stress. In light of this and upon closer 
observation of the literature two aspects may predict whether a stress-induced increase in Hcy 
levels occurs or not: the age of the individual and the duration of stress exposure. While 
Stoney (1999) was able to detect a Hcy increase in middle-aged to older women between 40 
and 64 years of age after a 10-minute stress exposure, Farag and colleagues (2003) were 
unable to replicate this finding in women of a similar age group as well as in younger women 
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aged between 21 and 41 years after only six minutes of stress exposure. Sawai and colleagues 
(2008), on the other hand, found that young men between 22 and 26 years of age showed an 
increase in Hcy after 15 minutes of stress exposure. In contrast, our younger age group 
showed no increase in Hcy after 10 minutes of stress exposure, while men between 40 and 65 
years of age showed an Hcy increase after 10 minutes of stress exposure. Notably, the studies 
used mental stressors of mild to moderate (e.g. arithmetics only) or stronger (arithmetics plus 
public speaking) stress reactivity inducing capacity.  
What are the underlying mechanisms of the observed Hcy stress increase in the older 
group? It is unlikely that the observed Hcy increase is a concomitant phenomenon of stress-
hemoconcentration (Austin et al., 2011) as the molecular weight of Hcy (0.135 kDa) is 
substantially smaller than the critical molecular weight of 69 kDa. We can only speculate that 
underlying mechanisms may include altered Hcy metabolism regulation (Williams and 
Schalinske, 2007) or altered sensitivity to stress hormone release (Rohleder et al., 2002) with 
age. We further speculate that the observed age effects on Hcy stress reactivity might be 
linked to norepinephrine/epinephrine levels which are released in response to acute stress 
from the adrenal medulla into circulation. Our speculation is based on the fact that Hcy 
synthesis is promoted by s-adenosylmethionine-dependent methylation of norepinephrine to 
form epinephrine (Gellekink et al., 2007). However, experimental studies are needed to 
determine exactly whether norepinephrine or epinephrine play a role in Hcy stress reactivity 
in different age groups.   
Our study has several strengths, including recruitment of apparently healthy and 
unmedicated subjects with reasonable health habits. This is important, because blood Hcy is 
affected by numerous lifestyle factors and drugs (Refsum et al., 1998; Castro et al., 2006). 
Furthermore, we statistically controlled for the potential confounding factors BMI, MAP, 
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vitamin B6, folate, and creatinine. We also used a highly standardized and potent stress test 
that reliably induces neuroendocrine stress responses (Dickerson and Kemeny, 2004).  
However, the study also has its limitations. First of all, the clinical relevance of the 
observed short-term Hcy increases with older age needs to be investigated in future research. 
Moreover, although our study provides first indications that aging affects stress reactivity of 
Hcy, based on our sample, no inference can be made at what age Hcy stress reactivity starts to 
increase. Large-scale studies are needed to address these questions. Furthermore, the 
underlying mechanisms of the observed age effect remain to be elucidated and Hcy reactivity 
in interaction with age should also be investigated following repeated acute stress induction. 
Moreover, our findings were obtained in a sample of apparently healthy men and may not be 
generalized to individuals with overt CVD or women.  
Taken together, we found first indications that age affects the Hcy response to stress. 
We observed Hcy stress reactivity in middle-aged to older but not in younger men. Given the 
association of mild to moderate hyperhomocysteinemia with atherogenesis and 
thrombogensis, our findings possibly point to a mechanism by which mental stress increases 
CVD risk in older individuals. However, the clinical relevance of our findings needs to be 
investigated and future studies are needed to replicate our findings in larger samples with 
broader age ranges. Moreover, the underlying mechanism of Hcy increases following stress 
with older age remains to be elucidated.  
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Figure legends 
Figure 1  
Changes of salivary cortisol to psychosocial stress in younger and middle-aged to older 
subjects. Values are mean ± SEM. Repeated measures ANOVA revealed significant salivary 
cortisol increases in response to stress across both age groups (main effect of stress in the total 
group: F(2.6/121.6) = 26.82, p = <.001, η2 = .36, main effect of stress in the younger group: 
F(2.6/67.7) = 11.73, p < .001, η2 = .31; main effect of stress in the older group: F(1.6/32.3) = 
26.90, p < .001, η2 = .57)). 
 
Figure 2  
Changes of plasma homocysteine levels to psychosocial stress in younger and middle-aged to 
older subjects. Values are mean ± SEM. Repeated measures ANCOVA revealed that the two 
age groups differed in Hcy stress reactivity (p = .014). More precisely, as shown by post hoc 
tests a Hcy increase following stress could be observed in the older (p = .022) but not in the 
younger group (p = .27). Body mass index, mean arterial pressure, vitamin B12, folate, and 
creatinine were controlled as covariates. 
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Tables 
Table 1 Characteristics in 50 subjects by age categorization 
 Younger group 
(n = 28) 
Older group 
(n = 22) 
P-
ANOVA 
Age (yr) 24.7±0.5 (20-30) 55.8±1.2 (47-65) <.001 
BMI (kg/m2) 23.2±0.4 (20.7-28.5) 26.3±0.4 (2.4-31.4) <.001 
MAP (mm Hg) 90.4±1.6 (71.2-103.3) 106.9±2.9 (81.7-138.0) <.001 
Hcy (μmol/L) 11.7±1.6 (6.1-41.2) 17.8±3.0 (7.4-47.1) .033 
Vitamine B12 (pg/ml) 493.3±36.6 (229-1012) 446.0±49.4 (295-1424) .436 
Folate (ng/ml) 6.2±0.6 (2.5-15.6) 6.0±0.7 (2.6-15.0) .807 
Creatinine (mg/dl) 1.0±0.02 (0.8-1.3) 1.0±0.03 (0.79-1.4) .315 
Cortisol baseline (nmol/l) 13.3±2.3 (4.3-52.2) 7.7±0.8 (2.1-18.9) .041 
Notes. Values are given as means±SEM. BMI, body mass index; MAP, mean arterial 
pressure; Hcy, homocysteine. 
 
